Advertisement
Coronavirus vaccine: Russia moves a step ahead of China with clinical trial data release
- Developer publishes results of phase 3 trials in peer-reviewed journal, bolstering credibility of shots, experts say
- Study shows ‘clear outcome and scientific principle of vaccination’
Reading Time:3 minutes
Why you can trust SCMP
38
A peer review of data has boosted the credibility of a Russian-made coronavirus vaccine dogged by transparency concerns, raising hopes that the shot can help ease global shortages, according to medical specialists.
The assessment comes after The Lancet medical journal published results on Tuesday indicating that the Sputnik V vaccine had an efficacy rate of nearly 92 per cent against Covid-19.
The Lancet article was based on an interim analysis of a trial involving nearly 20,000 people in Russia.
Advertisement
The Russian doses, developed by the Gamaleya Institute in Moscow, have been ordered by various countries as much of the global supply of other vaccines has been claimed by rich nations.
02:03
Russia approves ‘world’s first’ Covid-19 vaccine, President Vladimir Putin says
Russia approves ‘world’s first’ Covid-19 vaccine, President Vladimir Putin says
In August, authorities in Russia made the surprise move of granting the vaccine candidate domestic approval before its phase 3 trials.
Advertisement
Advertisement
Select Voice
Select Speed
1.00x